Avalanche Biotechnologies raises $5.7M for eye treatment

November 27, 2013 by Brad Perriello

Avalanche Biotechnologies raises nearly $5.7 million for its treatment for age-related macular degeneration.

Avalanche Biotechnologies raises $5.7M for eye drug/device combo

Avalanche Biotechnologies said it raised nearly $5.7 million of a hoped-for $6.1 million equity round for the age-related macular degeneration treatment it's developing.

The Avalanche technology is a drug-delivery system designed to trigger the production of a therapeutic protein by the body's own cells, creating what the company calls a "Bio-Factory" in the patient's eye, according to its website.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp